Business Wire

Vaultree Achieves Google Cloud Ready - AlloyDB Designation

29.3.2023 16:00:00 EEST | Business Wire | Press release

Share

Vaultree, the Data-In-Use Encryption leader, today announced that it has successfully achieved Google Cloud Ready - AlloyDB designation for AlloyDB for PostgreSQL, Google Cloud’s newest fully managed PostgreSQL-compatible database service for most demanding enterprise database workloads.

This market-expanding milestone follows Vaultree’s successful $12.8 million series A funding round, selection as the only Irish recipient of the European Innovation Council (EIC) grant and the appointment of renowned tech industry veteran Rinki Sethi to its executive board of directors.

Google Cloud Ready - AlloyDB is a new designation for the solutions of Google Cloud’s technology partners that integrate with AlloyDB. These partners have closely collaborated with Google Cloud to add support for AlloyDB into their solutions and tune their existing functionality for optimal outcomes. This designation recognizes the partner solutions that have met a core set of functional requirements and been validated in collaboration with Google Cloud engineering teams.

“Achieving the Google Cloud Ready - AlloyDB designation demonstrates that Vaultree’s data encryption in use capabilities have been validated by Google Cloud to integrate with AlloyDB to provide an excellent experience for customers,” said Ritika Suri, Director, Technology Partnerships at Google Cloud.

By earning this designation, Vaultree has proven its product has met a core set of functional and interoperability requirements when integrating with AlloyDB and refined documentation for ease of onboarding by the companies’ mutual customers. This designation enables customers to discover and have confidence that the Vaultree products they use today work well with AlloyDB and save time evaluating them.

As part of the program, Vaultree enjoys more opportunities to collaborate closely with Google Cloud partner engineering and AlloyDB teams to develop joint roadmaps.

Google Cloud’s ecosystem is designed to support industry-focused digital transformation. With this partnership, Vaultree enables customers to rely on end-to-end solutions through a reliable, fast and seamless integration of the most advanced encryption product on the market to rid themselves of the danger of plaintext data exposure.

“Breaches or leaks will continue to happen, no matter how many tools are in the first line of defense, but the second line of defense – encryption – has been neglected for decades because data still has to be decrypted in order to be worked with,” said Tilo Weigandt, COO and co-founder of Vaultree. “Our goal is to end that with our product and help enterprises to not just be compliant but secure and leave the worries behind.”

Vaultree with Google Cloud’s AlloyDB for PostgreSQL fulfills this goal, allowing customers to choose what to encrypt, and manage their own keys with zero learning and changes to the existing query languages, data structure, architecture, network topology or policies/permissions — all with minimal performance loss in the cloud.

“We are paving the way to a new era of cloud-based data protection by designing and offering the world’s first always-encrypted, Data-In-Use solution with unparalleled performance and simplicity, powered by Vaultree with Google’s AlloyDB for PostgreSQL,” said Ryan Lasmaili, CEO and co-founder of Vaultree. “Partnering with Google Cloud brings us reliability, flexibility and freedom to innovate and engage with a key player in an ever-changing industry to create the best data privacy solutions for enterprises of any kind, driving security and profitability, and accelerating digital transformation.”

To learn more about Vaultree’s expertise with AlloyDB, visit. To learn more about Google Cloud Ready - AlloyDB and its benefits, visit.

About Vaultree

Vaultree has developed the world’s first Fully Functional Data-in-Use Encryption solution that solves the industry’s fundamental security issue: persistent data encryption, even in the event of a leak. Vaultree enables enterprises, including those in the financial services and healthcare/pharmaceutical sectors, to mitigate the great financial, cyber, legal, reputational and business risk of a data breach in plain text. With Vaultree, organizations process, search and compute ubiquitous data at scale, without ever having to surrender encryption keys or decrypt server-side. If a leak occurs, Vaultree’s Data-In-Use encryption persists, rendering the data unusable to bad actors. Integrating Vaultree into existing database technologies is seamless, requiring no technology or platform changes. Vaultree is a privately held company based in Ireland and the U.S. For more information, please visit www.vaultree.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Matt Culbertson
prforvaultree@bospar.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level

Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release

Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye